Medical Developments International LimitedASX: MVP

Appendix 4C and Quarterly Activity Report -30 September 2026

· Issued by Medical Developments International Limited via ASX

Filed with ASX · · 9 pages · English

Summary by 6ix AI

The report highlights strong demand for Penthrox, particularly in Europe, and notes a slight decrease in group sales revenue compared to the previous year, attributed to inventory adjustments. The report outlines strategic priorities for the fiscal year, including expanding Penthrox into new markets and segments, particularly in the Middle East and North Africa region.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/appendix-4c-and-quarterly-activity-report-30-september-2026

Watch Medical Developments International's latest callMedical Developments International (ASX:MVP) Q4 2026 Earnings Call · Replay · Aug 19Read the transcript of Medical Developments International (ASX:MVP) Q4 2026 Earnings Call

Release

Medical Developments International Limited ABN 14 106 340 667 4 Caribbean Drive Scoresby Victoria 3179 Australia Postal Address PO Box 9004 Scoresby Victoria 3179 Australia Telephone +61 3 9547 1888 Fax +61 3 9547 0262 Web www.medicaldev.com 15 October 2026 ASX ANNOUNCEMENT QUARTERLY...

Medical Developments International Limited on 6ix

Story so far

Earlier from Medical Developments International

All Medical Developments International news releases